STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Cidara Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Cidara Therapeutics, Inc. (CDTX) received a Schedule 13G/A reporting that Point72-affiliated entities and Steven A. Cohen beneficially own 1,527,930 shares of common stock, representing 7.6% of the outstanding class as of June 30, 2025. The filing states those shares are held for investment by Point72 Associates and that Point72 Asset Management and Point72 Capital Advisors maintain shared voting and dispositive power over the shares; none of the reporting persons claim sole voting or dispositive power. The reporting address is 72 Cummings Point Road, Stamford, CT.

Positive

  • Disclosure of material stake: Reporting persons openly disclose a 7.6% ownership position (1,527,930 shares), meeting regulatory transparency requirements
  • Position classified as passive: The filing is a Schedule 13G/A indicating the shares are held for investment, not to change or influence control

Negative

  • No sole voting or dispositive power: Each reporting person reports 0 shares of sole voting and sole dispositive power, which may limit direct influence
  • Shared control only: All reported authority is shared (1,527,930 shares), potentially diluting clear accountability for engagement

Insights

TL;DR: Point72-affiliated holders disclose a material 7.6% passive stake in CDTX held for investment, with shared voting power.

The Schedule 13G/A shows a notable institutional position: 1,527,930 shares (7.6%), reported as passive and held by Point72 Associates under management of Point72 Asset Management. The filing clarifies shared voting and dispositive power but no sole control, and includes the standard certification that the position is not intended to influence control of the issuer. For investors, an ownership stake above 5% from a hedge-fund-affiliated manager is material for liquidity and potential shareholder engagement, but the filing explicitly characterizes the position as passive.

TL;DR: Reporting persons disclose shared authority and classify the position as passive; no group formation or control claim is made.

The document identifies reporting persons (Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen) and states shared voting/dispositive power of 1,527,930 shares. There is no indication of a group seeking control, no identification of additional members, and the form is a 13G (passive). From a governance perspective, this filing signals ownership transparency without an immediate change in board-control dynamics.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025

FAQ

How many Cidara Therapeutics (CDTX) shares do Point72-affiliated filers report owning?

The filers report beneficial ownership of 1,527,930 shares of CDTX common stock.

What percentage of CDTX does the reported position represent?

The reported position represents 7.6% of the outstanding class as of June 30, 2025.

Who are the reporting persons on the Schedule 13G/A for CDTX?

The statement is filed by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen.

Does any reporting person claim sole voting or dispositive power over the shares?

No. Each reporting person reports 0 shares of sole voting power and sole dispositive power; all authority is reported as shared.

As of what date is the ownership information reported?

The ownership amounts are reported as of the close of business on June 30, 2025.

What classification and purpose does the filing state for the position?

The filing is a Schedule 13G/A and includes a certification that the securities were not acquired for the purpose of changing or influencing control of the issuer (position described as passive).
Cidara Theraptcs

NASDAQ:CDTX

CDTX Rankings

CDTX Latest News

CDTX Latest SEC Filings

CDTX Stock Data

6.90B
31.09M
0.89%
107.06%
8.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO